249 related articles for article (PubMed ID: 8810612)
21. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
22. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
23. Assessment of serum CYFRA 21-1 in lung cancer.
Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
[TBL] [Abstract][Full Text] [Related]
24. [CYFRA 21-1: initial experiences in bronchus carcinoma and other tumors].
Hoefliger M; Morant R; Riesen W; Baumgartner G; Engler H
Schweiz Med Wochenschr; 1994 Nov; 124(44):1966-70. PubMed ID: 7973529
[TBL] [Abstract][Full Text] [Related]
25. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
26. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
27. Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer.
Pujol JL; Cooper EH; Grenier J; Purves DA; Lehmann M; Ray P; Aouta MD; Bashir M; Godard P; Michel FB
Eur J Cancer; 1994; 30A(12):1768-74. PubMed ID: 7880603
[TBL] [Abstract][Full Text] [Related]
28. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
29. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.
Pujol JL; Boher JM; Grenier J; Quantin X
Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer.
Giovanella L; Ceriani L; Bandera M; Beghe B; Roncari G
Int J Biol Markers; 1995; 10(3):156-60. PubMed ID: 8551058
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas.
Karnak D; Ulubay G; Kayacan O; Beder S; Ibis E; Oflaz G
Lung; 2001; 179(1):57-65. PubMed ID: 11479694
[TBL] [Abstract][Full Text] [Related]
33. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B
Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168
[TBL] [Abstract][Full Text] [Related]
34. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group.
Rastel D; Ramaioli A; Cornillie F; Thirion B
Eur J Cancer; 1994; 30A(5):601-6. PubMed ID: 7521651
[TBL] [Abstract][Full Text] [Related]
35. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
36. [Level of cytokeratin-19 in serum of patients with non small cell lung cancer].
Cynowska B; Słomiński JM; Wyrwiński J
Pneumonol Alergol Pol; 1995; 63(11-12):615-20. PubMed ID: 8616476
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer.
Hirashima T; Takada M; Komiya T; Nitta T; Masashi K; Masuda N; Matui K; Kikui M; Yasumitsu T; Kawase I
Anticancer Res; 1998; 18(6B):4713-6. PubMed ID: 9891546
[TBL] [Abstract][Full Text] [Related]
39. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases.
Stieber P; Dienemann H; Hasholzner U; Fabricius PG; Schambeck C; Weinzierl M; Poley S; Samtleben W; Hofmann K; Meier W
Int J Biol Markers; 1994; 9(2):82-8. PubMed ID: 7523546
[TBL] [Abstract][Full Text] [Related]
40. Serum and tissue distribution of a fragment of cytokeratin 19 (cyfra 21-1) in lung cancer patients.
Quillien V; Ramee MP; Bansard JY; Meritte H; Briens E; Logeais Y; Langanay T; Corbineau H; Dazord L
Anticancer Res; 1995; 15(6B):2857-63. PubMed ID: 8669879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]